CASI Pharmaceuticals Inc. (CASI)

Name: CASI Pharmaceuticals Inc. (CASI) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: CASI Pharmaceuticals Inc. (CASI)

Stock Card

$0.14

$-0.10 (-41.21%)

As on 24-Mar-2026 09:30EDT

Market cap

$4 Mln

Revenue (TTM)

$27 Mln

P/E Ratio

P/B Ratio

15.7

Div. Yield

0 %

CASI Pharmaceuticals (CASI) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.14 High: 0.16

52 Week Range

Low: 0.14 High: 3.09

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-10.9 %
ROCE

-- %
Industry P/E

37.91
EV/EBITDA

0.1
Debt to Equity

0
Book Value

$--
EPS

$-3.2
Face value

--
Shares outstanding

20,548,273

10 Years Aggregate

CFO

$-167.54 Mln

EBITDA

$-173.46 Mln

Net Profit

$-299.20 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
CASI Pharmaceuticals (CASI)	-83.2	-81.1	-81.0	-93.6	-56.5	-63.7	-37.0
BSE Sensex^*	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 24-Mar-2026 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2021	2020	2019
CASI Pharmaceuticals (CASI)	-70.0	-60.2	300.0	-72.9	-4.5	-23.1
S&P Small-Cap 600	4.0	7.0	13.9	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of... melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Read more

Chairman & CEO

Dr. Wei-Wu He Ph.D.
Chairman & CEO

Dr. Wei-Wu He Ph.D.
Headquarters

Beijing
Website

https://www.casipharmaceuticals.com

FAQs for CASI Pharmaceuticals (CASI)

What is the current share price of CASI Pharmaceuticals Inc (CASI) Today?

The share price of CASI Pharmaceuticals Inc (CASI) is $0.14 (NASDAQ) as of 24-Mar-2026 09:30 EDT. CASI Pharmaceuticals Inc (CASI) has given a return of -56.45% in the last 3 years.

What is the current PB & PE ratio of CASI Pharmaceuticals Inc (CASI)?

Since, TTM earnings of CASI Pharmaceuticals Inc (CASI) is negative, P/E ratio is not available.
The P/B ratio of CASI Pharmaceuticals Inc (CASI) is 15.65 times as on 24-Mar-2026, a 104 premium to its peers’ median range of 7.69 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-1.12	23.69
2023	-3.56	3.96
2022	-0.60	0.55
2021	-0.30	0.13
2020	-0.72	0.43

What is the 52 Week High and Low of CASI Pharmaceuticals Inc (CASI)?

The 52-week high and low of CASI Pharmaceuticals Inc (CASI) are Rs 3.09 and Rs 0.14 as of 06-Sep-2026.

What is the market cap of CASI Pharmaceuticals Inc (CASI)?

CASI Pharmaceuticals Inc (CASI) has a market capitalisation of $ 4 Mln as on 24-Mar-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in CASI Pharmaceuticals Inc (CASI)?

Before investing in CASI Pharmaceuticals Inc (CASI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.